We collected peripheral blood stem cells ( 
The hallmark of the disease is the presence of the Philadelphia chromosome which is the result of a reciprocal translocation between chromosomes 9 and 22. This leads to a juxtaposition of the BCR gene derived from chromosome 22 and the ABL gene, derived from chromosome 9. The gene product is a tyrosine kinase, which has increased activity compared to the normal ABL tyrosine kinase and which plays a central role in leukaemogenesis. 2 Characteristically, the disease takes an indolent course for 3-5 years before inevitably blastic transformation occurs, which is usually fatal within 3-6 months. Allogeneic stem cell transplantation (alloSCT) offers the only prospect of cure, but is applicable in only 15-30% of patients as a result of donor availability and age criteria. 3 Patients not eligible for alloSCT are currently treated with IFN␣-based therapies. IFN␣ has been shown to prolong survival when compared with conventional chemotherapies, like busulfan or hydroxyurea. [4] [5] [6] Recently, autologous stem cell transplantation (autoSCT) has received considerable attention in the treatment of CML. In several uncontrolled studies, it has been suggested that autoSCT may prolong the chronic phase of CML, but its value is unproven at present. 7, 8 Benign haematopoietic stem cells have been observed to coexist with their malignant counterparts in the bone marrow of patients with chronic phase CML. It is possible to harvest these normal Ph-negative progenitors from the peripheral blood following mobilization with growth factors in order to be reinfused after myeloablative therapy. A substantial portion of patients treated in this way revert, at least temporarily, to Ph-negative haemopoiesis. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The probability of reaching a major cytogenetic reponse after autoSCT may be related to the number of negative progenitors in the stem cell graft. 20 Generally, haemopoietic stem cells have been harvested in the early recovery phase after a single cycle of conventional intensive chemotherapy followed by G-CSF. We investigated whether an additional cycle of intensive chemotherapy would increase the number of Ph-negative progenitors in the harvest. Therefore we treated CML patients with two cycles of intensive chemotherapy, harvested peripheral blood stem cells after both cycles and performed autoSCT if one of these harvests showed a major cytogenetic response.
Patients and methods

Patients
Patients with newly diagnosed Ph-or bcr-abl positive CML were eligible for the study according to the following criteria: (1) first chronic phase р6 months after diagnosis (2) age between 16 and 65 years; (3) not eligible for HLAmatched allogeneic (sibling) donor transplantation; (4) WHO performance score 0 or 1. CML patients in accelerated or blastic phase were excluded, as well as patients with severe hepatic, renal, cardiac, pulmonary or neurological dysfunctions. Informed consent was obtained in all cases.
Chemotherapy and mobilisation procedures
A back-up stem cell collection was performed shortly after diagnosis. Patients were stabilised on hydroxyurea prior to start of the chemotherapy regimen. Induction therapy consisted of two courses of chemotherapy. Cycle one: cytarabine 200 mg/m 2 /day, days 1-7 (24 h continuous infusion); idarubicin 12 mg/m 2 /day, days 1-2 (bolus infusion). Cycle two was started as soon as there was evidence of haematopoietic regeneration after cycle one, with platelets Ͼ100 × 10 9 /l and polymorphonuclear cells (PMN) Ͼ1.5 × 10 9 /l, and consisted of cytarabine 1000 mg/m 2 every 12 h, days 1-6 (2 h infusion) and amsacrine 120 mg/m 2 /day, days 1-3 (1 h infusion). Granulocyte colony-stimulating factor (G-CSF, filgrastim; Neupogen, Amgen, Breda, The Netherlands) 10 g/kg/day s.c. was administered after each cycle as soon as the leukocytes started to recover above 0.5 × 10 9 /l until the last day of leukapheresis. Leukapheresis was performed as soon as leukocytes regenerated to у2 × 10 9 /l and significant numbers of CD34 + cells (Ͼ10 × 10 6 /l) had appeared in the peripheral blood. Peripheral blood stem cells (PBSC) were collected by leukapheresis using an automated blood cell separator (either Baxter CS 3000 Plus, Utrecht, The Netherlands or Cobe BCT Spectra, Veenendaal, The Netherlands). Mononuclear and progenitor cell content was assessed by conventional counting and flow cytometric analysis of CD34 + cells. CFU-GM content was evaluated using standard shortterm clonogenic assays of mononuclear cells in methylcellulose. Leukapheresis was continued until the collection contained at least 2 × 10 6 CD34 + cells/kg or 2 × 10 8 mononuclear cells (MNC)/kg. Cells were then processed, cryopreserved and stored in liquid nitrogen until use. Toxicity of the chemotherapy was graded according to the standard Common Toxicity Criteria.
Autologous PBSC transplantation
Patients were considered eligible for autologous PBSC transplantation (PBSCT) if they reached a major cytogenetic response in at least one of the PBSC harvests obtained after each cycle of chemotherapy. The conditioning regimen consisted of busulphan 4 mg/kg/day (per os), days −6 to −3 and melphalan 140 mg/m 2 (15 min infusion) on day −2 followed by reinfusion of cryopreserved stem cells on day 0. The harvest that showed the lowest number of Ph + cells after the first or the second chemotherapy cycle was reinfused. All patients received antibiotic prophylaxis, consisting of ciprofloxacine for gram-negative coverage, azithromycin or penicillin to prevent streptococcal septicaemia and fluconazole as an anti-fungal agent. Cytogenetic response was evaluated 1-3 months post transplantation, before the start of IFN␣ maintenance therapy.
IFN␣ maintenance therapy
After PBSCT, IFN␣ was given as soon as haematopoietic recovery was achieved. Patients ineligible for PBSCT received IFN␣ following haematopoietic recovery of the last cycle of intensive chemotherapy. The starting dose was 3 × 10 6 units three times weekly for 2 weeks. Thereafter, a dosage of 6 × 10 6 units daily was aimed for, with dose adjustments in order to keep the leukocytes between 2 and 5 × 10 9 /1 and platelets Ͼ75 × 10 9 /1. Bone marrow of the patients was evaluated cytogenetically every 6 months during treatment with IFN␣ as long as there was a complete haematological remission. Patients remained on IFN␣ as long as cytogenetic response was maintained and sideeffects were tolerated.
Cytogenetics
Samples of the leukapheresis harvest and bone marrow were cultured for 2 days in RPMI/10% FCS in the presence of 10 mm colcemid. Cells were fixed in methanol/acetic acid until use. Metaphase spreads were stained using standard G-banding techniques.
Interphase fluorescence in situ hybridisation (FISH)
This procedure has been described by us in detail. 21 Briefly, cytospin slides were prepared and subsequently dried, fixed in ethanol 70% and stored in −30°C until use. After RNAse treatment and digestion with pepsin, the slides were fixed in 1% formaldehyde in PBS. Denaturation at 72°C was followed by overnight hybridisation with bcr and abl cosmid probes, that were labeled by nick translation with digoxigenin-11-dUTP and biotin-14-dATP, respectively. After washing with standard saline citrate, the biotin labeled probe was detected by fluorescein-avidin DN, followed by biotinylated anti-avidin and fluorescein avidin. The digoxigenin labeled probe was detected by anti-digoxigenin-rhodamine, followed by Texas red-conjugated donkey antisheep. Samples were scored under an Axioscop 50 microscope (Carl Zeiss Jena, Jena, Germany). Nuclei were scored positive for the bcr-abl gene when a green and a red spot were less than one spot diameter apart.
Response assessment
Response to each cycle of chemotherapy was assessed by cytogenetic examination of a freshly obtained sample from a leukapheresis procedure, preferably the procedure which yielded the highest number of CD34 + cells. A bone marrow aspirate was simultaneously examined for comparative studies. At least 20 metaphases were analysed when available. Cytogenetic response was defined as follows: (1) 
Statistical analysis
Survival was calculated from the date of registration until death or last contact. Haematological recovery was determined from the first day blood counts were below the specified level. The Kaplan-Meier method was used to calculate actuarial recovery percentages. Results of cytogenetic and FISH analysis are presented as percentages of Ph-or bcrabl positivity respectively in the leukapheresis samples or bone marrow.
Results
Patient characteristics
From April 1995 to December 1997, 19 patients with CML in early chronic phase entered the study. Patients were recruited from four centres in The Netherlands and from one centre in Belgium. Patient characteristics are listed in Table 1 . Median age was 47 years (range 21-59). Median Sokal score was 0.94 (range 0.60-1.83, Ͻ0.8: n = 6; 0.8-1.2: n = 8; Ͼ1.2: n = 5). All patients showed a t(9;22) by cytogenetic analysis of bone marrow samples and the bcrabl rearrangement by RT-PCR analysis. Two patients had additional cytogenetic abnormalities: one patient had a constitutional t(4;13) in all cells and trisomy 8 was found in two out of 30 cells of another patient. All patients except one received hydroxyurea as prior treatment before starting the first cycle of chemotherapy. None of the patients had Table 2 .
Tolerability and toxicity of induction chemotherapy regimen
Following both cycles no severe toxicities other than infections and mucositis were documented. The median number of days with neutrophil counts below 0.5 × 10 9 /l was 19 (3-26) after the first and 18 (14-36) days after the second cycle of induction chemotherapy. Platelet counts were below 20 × 10 9 /l for 13 (median, range 8-28) and 16 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) days, respectively, and below 50 × 10 9 /l for 17 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) and 21 (14-37) days, respectively. Median numbers of platelet transfusions were three (1-16) and five (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , respectively, and those of red blood cell transfusions were six (range 2-17) after the first cycle and 10 (4-16) after the second.
Infections occurred in 53% (10/19) of the patients after cycle one and in 50% (8/16) of the patients after cycle two. Eight patients (six after cycle one, two after cycle two) showed positive blood cultures during periods of fever and were treated with antibiotics with a favourable response. Micro-organisms isolated were Staphylococcus epidermidis and Streptococcus mitis. Three patients developed a pneumonia. One patient (No. 5) died of a fungal pneumonia after the first cycle. Two other cases of pneumonia (one probably fungal and one probably bacterial) responded well to treatment. Two episodes of fever of unknown origin (FUO) were successfully treated with broad spectrum i.v. antibiotics. Table 2 also lists the cytogenetic responses achieved in the PBSC collections and in the bone marrow of the patients at follow-up. When cytogenetic analysis of the harvest failed, as occurred for some patients, response was evaluated by means of FISH analysis. Preferably, the same procedure was used for comparison of the response after cycle g initially only cytogenetic results of bone marrow available: 100% Ph-positivity. CP = chronic phase; AP = accelerated phase; BC = blast crisis; HU = hydroxyurea; MR = molecular remission.
Cytogenetic analysis
one vs that after cycle two. Evaluation of the harvests showed a cytogenetic (or in situ hybridisation) response in all patients after cycle one. Nine patients (47%) obtained a major (three complete, six partial) cytogenetic response (MCR). In no patient except one (patient 6) were results of cytogenetic or FISH analysis after cycle two superior to those after cycle one. In this patient however, there was a large discrepancy between the results of FISH analysis of the harvest compared with the cytogenetic analysis of the bone marrow after cycle two (18 vs 100% bcr-abl/Ph-positivity, respectively). Only a partial cytogenetic response could be observed after cycle two, in the harvest of eight patients (42%). No complete responses were observed. Evaluation of bone marrow samples showed no significant difference between cycle one and cycle two (see also Table 3 ).
PBSC transplantation
Nine patients qualified for autologous PBSCT. Of these nine patients with a MCR in the harvest obtained after cycle one, two patients went off protocol treatment. The other patients with a MCR in the harvest obtained after cycle one, also achieved a MCR in the harvest obtained after cycle two, and they all proceeded with autologous PBSCT. Two additional patients who did not qualify for autologous PBSCT were, however, transplanted. The myeloablative regimen was relatively well tolerated. No severe toxicities occurred. In one patient liver enzyme abnormalities developed, which were ascribed to fluconazole treatment. These responded well to dose adjustment.
No transplantation-related mortality ensued. Infections occurred in six out of nine (67%) patients. FUO occurred in three patients. Two other patients had bacteraemia due to Staphylococcus epidermidis during periods of fever and were treated with antibiotics until defervescence. Intravenous antibiotics or anti-fungals were required for a median of 11 days (range 5-21). One patient developed a Guillain-Barré syndrome of unknown cause several weeks post transplantation. There were no graft failures.
Neutrophil recovery to over 0.5 × 10 9 /l took a median of nine (7) (8) (9) (10) (11) (12) (13) (14) days, platelets were Ͻ20 × 10 6 /l for 10 (0-66) days. Patients stayed in a protected environment for a median of 21 days (range 17-27) and required hospitalisation for a median of 29 days (range [26] [27] [28] [29] [30] [31] [32] [33] . Bone marrow samples of the patients were evaluated 2-4 months post transplantation. Three patients had an MCR (one complete and two partial), and five patients had a minor response. In one patient response was absent. All proceeded with IFN␣.
Follow-up
As shown in Table 2 , in the group of transplanted patients, median follow-up of the eight patients still alive is 33 months (range 25-44 months). Only one patient was in a complete cytogenetic remission after transplantation. He relapsed after a period of 2 years. Two others attained a complete cytogenetic response after more than 1 year of therapy with IFN␣ and were 100% Ph-negative at 17 and 21 months after transplantation. The other patients reverted to predominantly Ph-positive haematopoiesis.
In the eight non-autoSCT patients who are still alive, median follow-up is 39 months (range 19-44 months). None of these patients attained a major cytogenetic response, although they were all treated with IFN␣ after autoSCT. Two patients underwent alloSCT. Current disease status and causes of death during follow-up (if applicable) are also shown in Table 2 .
Discussion
The use of autologous stem cells for SCT in CML is supported by the observation that, in chronic phase CML, Phnegative progenitors co-exist with malignant progenitors. 22 In this study, we were able to obtain preferentially Ph-negative harvests in almost 50% of early chronic phase CML patients treated with AML-based intensive chemotherapy. In AML, leukapheresis for autologous transplantation is generally performed after two, instead of one, cycles of chemotherapy, 23 assuming that tumor contamination of the harvest will be less after two cycles of chemotherapy. In our group of 19 early chronic phase CML patients, an additional cycle of high-dose chemotherapy for stem cell mobilization did not improve the yield of bcr-abl negative progenitors. It is not likely that differences in the level of myelosuppression after the successive cycles of chemotherapy account for this phenomenon, because the pancytopenic period was longer and mean CFU-GM counts were lower after the second course than after the first in both patient groups (transplanted and non-transplanted). In the Bone Marrow Transplantation transplanted patients, mean CD34 + counts were also lower after cycle 2.
It is possible that responses after the second cycle of chemotherapy could be impaired by removal of a substantial portion of Ph-negative progenitors by leukapheresis after the first cycle, leading to a rather unfavourable starting point for the second cycle of chemotherapy. That explanation remains hypothetical since we do not know how many normal progenitors exist in early chronic phase CML and what proportion of them can be removed by leukapheresis. An alternative explanation could be that CML progenitor cells, as compared to their normal counterparts, are more apt to survive chemotherapy as a consequence of resistance to apoptosis caused by the bcr-abl gene, [24] [25] [26] [27] [28] [29] [30] [31] which could result in the selection of Ph + -progenitors at the cost of normal progenitors.
Several methods have been used to mobilise Ph-negative progenitors with variable success rates. An overview of published mobilisation studies with у15 CML patients is given in Table 4 . As is evident from the data presented herein, results of mobilisation in terms of Ph-negativity are improved in early chronic phase compared to later stages of the disease. Even within the first year, very early mobilisation may be advantageous considering the superior results that several investigators attained when mobilising patients within a few months after the diagnosis was made.
12,32-34 Also, 'ICE' or 'mini-ICE' seems to be more effective chemotherapy in mobilising Ph-negative progenitors in more advanced stages of the disease than conventional '3 + 7' or '5 + 2' daunorubicin and cytarabine chemotherapy.
In only one study, more than one cycle of intensive chemotherapy was given before harvesting of (bone marrow) stem cells. 35 A positive effect on the elimination of malignant progenitors was suggested. Ph-negativity increased after consecutive cycles of intensive chemotherapy. In particular, the first two cycles were effective in decreasing the number of Ph-negative progenitors, while the third cycle had only a minor effect. If Ph-negativity occurred after one to three cycles, bone marrow was harvested and patients were autotransplanted, yielding posttransplant cytogenetic remissions of various duration and an overall survival that seemed to be better than that of a group of age-matched historical controls. 36 These favourable results may suggest that intensive chemotherapy also effectively reduces the leukemic burden in the patient, apart from a graft-purging effect. Thus, according to the data listed in Table 4 , at least 50% major cytogenetic responses may be achieved with current mobilisation regimens, primarily depending on disease stage. This figure is comparable with our results after the first cycle of chemotherapy in early chronic phase CML. Probably, the earlier the mobilisation takes place, the better the results may be.
It is still unclear whether autologous stem cell transplantation improves survival in CML. Several uncontrolled studies suggest it does, 37 but no randomised controlled trials have been published yet. Studies reported so far suggest that intensive chemotherapy and autoSCT followed by IFN␣ may improve results as compared to IFN␣ alone. 38 In addition, it has been shown that patients who do not respond cytogenetically to IFN␣, may revert to IFN␣ responsiveness after intensive chemotherapy and autoSCT. 39, 40 All these studies suggest an additive effect of intensive chemotherapy to an already impressive antileukaemic activity of IFN␣ alone. A prospective randomised trial under the auspices of the EBMT addressing the question whether autoSCT followed by IFN␣ vs IFN␣ alone improves survival is currently being performed.
A potential disadvantage of autografting is the reinfusion of malignant progenitors especially when patients do not show a major cytogenetic response of the PBSC harvest. Findings by Talpaz et al 20 have suggested that the probability of achieving a cytogenetic response after autoSCT may depend on the percentage of normal progenitors in the PBSC graft. These findings do not argue against intensive chemotherapy, but they question the applicability of autoSCT. In order to avoid such a potential problem, the Dutch-Belgian HOVON group has set out to prospectively compare standard treatment (IFN␣ and low-dose cytarabine) vs intensive chemotherapy including high-dose cytarabine followed by IFN␣, but without autoSCT.
We conclude that Ph-negative peripheral blood progeniBone Marrow Transplantation tor cells are preferentially harvested after a single course of intensive chemotherapy. For autografting purposes, a second cycle of chemotherapy does not improve Ph-negativity in the graft. Whether intensive chemotherapy with or without autoSCT has a role in delaying transformation in CML is the issue of several randomized trials that are now underway. The role of the newly introduced tyrosine kinase inhibitor STI-571 still has to be fully investigated but it certainly is to be expected that this drug will change our treatment of CML in view of the very promising results recently reported. 41 Future studies will have to address the question if addition of STI-571 to existing mobilisation schemes will lead to better results of autografting procedures.
